These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. The energetics of ligand binding at catecholamine receptors. Strange PG Trends Pharmacol Sci; 1996 Jul; 17(7):238-44. PubMed ID: 8756182 [TBL] [Abstract][Full Text] [Related]
64. Mu-opioid receptor heterooligomer formation with the dopamine D1 receptor as directly visualized in living cells. Juhasz JR; Hasbi A; Rashid AJ; So CH; George SR; O'Dowd BF Eur J Pharmacol; 2008 Mar; 581(3):235-43. PubMed ID: 18237729 [TBL] [Abstract][Full Text] [Related]
65. [Mechanism of apoptosis-inducing effects of dopamine on K562 leukemia cells]. Yuan LB; He Q; Guo YM Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 Mar; 36(2):191-5. PubMed ID: 17443910 [TBL] [Abstract][Full Text] [Related]
66. Using a staged multi-objective optimization approach to find selective pharmacophore models. Clark RD; Abrahamian E J Comput Aided Mol Des; 2009 Nov; 23(11):765-71. PubMed ID: 18663585 [TBL] [Abstract][Full Text] [Related]
67. Dopamine D2 receptors form higher order oligomers at physiological expression levels. Guo W; Urizar E; Kralikova M; Mobarec JC; Shi L; Filizola M; Javitch JA EMBO J; 2008 Sep; 27(17):2293-304. PubMed ID: 18668123 [TBL] [Abstract][Full Text] [Related]
68. Interaction Between the Angiotensin-(1-7) Mas Receptor and the Dopamine D2 Receptor: Implications in Inflammation. Rukavina Mikusic NL; Silva MG; Mazzitelli LR; Santos RAS; Gómez KA; Grecco HE; Gironacci MM Hypertension; 2021 May; 77(5):1659-1669. PubMed ID: 33677980 [TBL] [Abstract][Full Text] [Related]
69. Comparison of 87Rb N-resonances for D1 and D2 transitions. Novikova I; Phillips DF; Zibrov AS; Walsworth RL; Taichenachev AV; Yudin VI Opt Lett; 2006 Aug; 31(15):2353-5. PubMed ID: 16832483 [TBL] [Abstract][Full Text] [Related]
70. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease. Bezard E; Gray D; Kozak R; Leoni M; Combs C; Duvvuri S CNS Neurol Disord Drug Targets; 2024; 23(4):476-487. PubMed ID: 36999711 [TBL] [Abstract][Full Text] [Related]
71. Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal. Iasevoli F; Avagliano C; D'Ambrosio L; Barone A; Ciccarelli M; De Simone G; Mazza B; Vellucci L; de Bartolomeis A Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979877 [TBL] [Abstract][Full Text] [Related]
72. Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression? Zhao F; Cheng Z; Piao J; Cui R; Li B Front Pharmacol; 2022; 13():947785. PubMed ID: 36059987 [TBL] [Abstract][Full Text] [Related]
73. Class A and C GPCR Dimers in Neurodegenerative Diseases. Caniceiro AB; Bueschbell B; Schiedel AC; Moreira IS Curr Neuropharmacol; 2022; 20(11):2081-2141. PubMed ID: 35339177 [TBL] [Abstract][Full Text] [Related]
74. Luminescence- and Fluorescence-Based Complementation Assays to Screen for GPCR Oligomerization: Current State of the Art. Wouters E; Vasudevan L; Crans RAJ; Saini DK; Stove CP Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31213021 [TBL] [Abstract][Full Text] [Related]
75. Dopamine: Functions, Signaling, and Association with Neurological Diseases. Klein MO; Battagello DS; Cardoso AR; Hauser DN; Bittencourt JC; Correa RG Cell Mol Neurobiol; 2019 Jan; 39(1):31-59. PubMed ID: 30446950 [TBL] [Abstract][Full Text] [Related]
76. GPCRs and Signal Transducers: Interaction Stoichiometry. Gurevich VV; Gurevich EV Trends Pharmacol Sci; 2018 Jul; 39(7):672-684. PubMed ID: 29739625 [TBL] [Abstract][Full Text] [Related]
77. Acute cocaine exposure elicits rises in calcium in arousal-related laterodorsal tegmental neurons. Lambert MØ; Ipsen TH; Kohlmeier KA Pharmacol Res Perspect; 2017 Feb; 5(1):e00282. PubMed ID: 28596834 [TBL] [Abstract][Full Text] [Related]
78. Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation. Rico AJ; Dopeso-Reyes IG; Martínez-Pinilla E; Sucunza D; Pignataro D; Roda E; Marín-Ramos D; Labandeira-García JL; George SR; Franco R; Lanciego JL Brain Struct Funct; 2017 May; 222(4):1767-1784. PubMed ID: 27612857 [TBL] [Abstract][Full Text] [Related]
79. Dopamine D1 and corticotrophin-releasing hormone type-2α receptors assemble into functionally interacting complexes in living cells. Fuenzalida J; Galaz P; Araya KA; Slater PG; Blanco EH; Campusano JM; Ciruela F; Gysling K Br J Pharmacol; 2014 Dec; 171(24):5650-64. PubMed ID: 25073922 [TBL] [Abstract][Full Text] [Related]